Search company, investor...

Agios Pharmaceuticals

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price




About Agios Pharmaceuticals

Agios Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of therapeutics in the field of cancer metabolism. To support and drive these efforts, Agios has built a platform integrating cancer biology, metabolomics, biochemistry and informatics to enable target and biomarker identification. Agios' capabilities to interrogate differential cellular metabolism of diseased cells relative to normal cells may also be applicable to other therapeutics areas including autoimmune, inflammatory and neurological diseases.

Headquarters Location

88 Sidney Street

Cambridge, Massachusetts, 02139,

United States


Missing: Agios Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Agios Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Agios Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Agios Pharmaceuticals is included in 3 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Agios Pharmaceuticals Patents

Agios Pharmaceuticals has filed 129 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • EC 1.1.1
  • Metabolism
patents chart

Application Date

Grant Date


Related Topics




Blood disorders, Hereditary hemolytic anemias, Red blood cell disorders, Hematopathology, Blood tests


Application Date


Grant Date



Related Topics

Blood disorders, Hereditary hemolytic anemias, Red blood cell disorders, Hematopathology, Blood tests



Latest Agios Pharmaceuticals News

Agios Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Agios Pharmaceuticals founded?

    Agios Pharmaceuticals was founded in 2008.

  • Where is Agios Pharmaceuticals's headquarters?

    Agios Pharmaceuticals's headquarters is located at 88 Sidney Street, Cambridge.

  • What is Agios Pharmaceuticals's latest funding round?

    Agios Pharmaceuticals's latest funding round is IPO.

  • How much did Agios Pharmaceuticals raise?

    Agios Pharmaceuticals raised a total of $140.28M.

  • Who are the investors of Agios Pharmaceuticals?

    Investors of Agios Pharmaceuticals include ARCH Venture Partners, Flagship Pioneering, Third Rock Ventures, Celgene, Qualifying Therapeutic Discovery Project and 4 more.

  • Who are Agios Pharmaceuticals's competitors?

    Competitors of Agios Pharmaceuticals include Biolog, Longevica, Noveome Biotherapeutics, Threshold Pharmaceuticals, Celator Pharmaceuticals and 16 more.

Compare Agios Pharmaceuticals to Competitors

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Stem Cells Bank

Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.

Animal Cell Therapies

Animal Cell Therapies is a biotech firm that aims to improve the lives of animals through thoughtful research and development. The ACT team is focused on developing and delivering cellular treatment and services to customers.

Cellerant Therapeutics Logo
Cellerant Therapeutics

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.

CDI Bioscience

CDI Bioscience is a biopharmaceutical technology company with a patented process that can increase the productivity of cells in the manufacture of therapeutic proteins. The Madison, Wis-based company's patented process, based on its RP Shift technology, encourages cells to routinely produce three to seven times more therapeutic protein than they normally would. The process controls cell metabolism, shifting a cell from replicative mode (division of a cell) to production mode (increased protein synthesis). Battelle Ventures and its affiliate fund, Innovation Valley Partners, were the sole investors in the $3-million Series A round. General Partner Mort Collins is chairman of the Board of Directors. (See deal announcement.)

Biosceptre International

Biosceptre has identified a pan-cancer target, present in many cancer types, and importantly not found in healthy tissue. Early research and initial evidence suggest that drugs directed at the nf-P2X7 target have the potential to redefine cancer therapy. The Company has raised AUD33m and will be raising further capital through both existing and new investors. Biosceptre has a rigorous, international patent portfolio extending to 2032, providing broad protection of the target and specific protection of antibody products. The Company is developing therapeutics and diagnostics to bind nf-P2X7, with the core of product development in topical and systemic cancer drugs. Biosceptreis also developing an immuno-oncology vaccine, through an existing collaboration, and is in discussions with developmental partners to develop diagnostic and imaging technologies to detect and monitor cancer. Biosceptre is supported by a world-class scientific advisory board, the members of which have been central in the development of numerous, highly successful, biotechnology companies and products. The Company has the team, capital, and plan to create substantial value from this unique, patent-protected, technology. The business is headquartered in Cambridge, UK with additional research facilities in Sydney, Australia.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.